Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 12, 2011

ExcellGene Extends Supply Agreement for Polyplus-Transfection's Reagents

  • ExcellGene, a provider of solutions for protein manufacturing and process development based on mammalian cells, has signed an extended supply agreement for polyethylenimine (PEI)-based transfection reagents produced by Polyplus-transfection.

    The company will supply ExcellGene with batches of linear PEI transfection reagents that are designed to ensure reliable, safe, and reproducible protein production in the medium-to-large scale ranges. By purchasing PEI from Polyplus-transfection, ExcellGene benefits from Polyplus’ intellectual property rights for the use of PEI in transient and stable transfection. Polyplus-transfection supplies its reagents for the transfection of genes, oligonucleotides, and siRNA.

    ExcellGene says that it has attracted more than 100 international clients. The firm's offerings cover vectors, gene transfer systems, cell hosts, screening platforms for cells and processes, scale-up principles, and bioreactors. Last year, the company won approval from the Swiss regulatory agency for production of APIs at its cGMP manufacturing facility, which features bioreactors of up to 250 L.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »